Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC

Documents similaires

• Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.
  par: Hanrahan, E, et autres
  Publié: (2009)
• Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.
  par: Hanrahan, E, et autres
  Publié: (2010)
• Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474).
  par: Siemann, D, et autres
  Publié: (2009)
• Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
  par: Wells, SA, et autres
  Publié: (2012)
• Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study
  par: Christina L. Addison, et autres
  Publié: (2015-06-01)